FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2044865080> ?p ?o ?g. }

• W2044865080 endingPage "2091" @default.
• W2044865080 startingPage "2090" @default.
• W2044865080 abstract "In Her2/neu growth factor overexpressing poor prognosis breast cancers trastuzumab has shown to improve disease-free survival as well as overall survival in metastatic and primary diseases. On the basis of these positive results, trastuzumab has also been included into studies of neo-adjuvant therapy of Her2/neu-positive T2 tumors [1.Coudert B.P. Arnould L. Moreau L. et al.Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial.Ann Oncol. 2006; 17: 409-414Abstract Full Text Full Text PDF PubMed Scopus (91) Google Scholar]. In our previous report on neo-adjuvant treatment, the initial reduction in circulating epithelial tumor cells (CETC) highly correlated to tumor size reduction [2.Pachmann K. Camara O. Kavallaris A. et al.Quantification of the response of circulating epithelial cells (CEC) to neodadjuvant treatment of breast cancer: a new tool for therapy monitoring.Breast Cancer Res. 2005; 7: R975-R979Crossref PubMed Scopus (69) Google Scholar] but further tumor shrinkage led to massive cell release [3.Camara O. Rengsberger M. Egbe A. et al.The relevance of circulating epithelial tumour cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer.Ann Oncol. 2007; 18: 1484-1492Abstract Full Text Full Text PDF PubMed Scopus (81) Google Scholar]. CETC from 26 Her2/neu-positive patients were further monitored during combined chemotherapy and antibody treatment [4.Lazaridis G. Pentheroudakis G. Pavlidis N. Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: accumulating evidence of efficacy, synergy and safety.Crit Rev Oncol Hematol. 2008; 66: 31-41Crossref PubMed Scopus (30) Google Scholar] and during follow-up. Typical such cells are shown in Figure 1A. Sixteen of the Her2/neu-positive patients were treated with four cycles of EC (epirubicine/cyclophosphamide) and four cycles of taxane (paclitaxel) together with trastuzumab and with trastuzumab for 1 year; thereafter. Six patients received trastuzumab only postoperatively and four patients did not receive trastuzumab at all. In all, 5 of 14 (36%) assessable for tumor response at surgery showed pathological complete response (pCR) compared with only 5 of 30 (17%) Her2/neu-negative patients. Relapse-free survival until now is 65% versus 77%, respectively, thus relapses are still more frequent in spite of a higher frequency of pCR in Her2/neu-positive patients. Patients who received taxane only showed a sharper increase in CETCs than patients treated with taxane/trastuzumab, the extent of increase being inversely correlated to the probability of relapse (Figure 1B) (P = 0.048). During postsurgery observation, 4 of 4 patients who did receive trastuzumab neither before nor after surgery all had increasing CETC numbers (Figure 1C) and all have suffered relapse already within 1.5 years from diagnosis. From the trastuzumab neo-adjuvant arm, 9 of 15 assessable patients showed decreasing numbers of CETC during the following year of trastuzumab treatment and eight of nine of these patients have remained relapse free. Only one patient has suffered relapse in the brain. Of the 6 of 15 patients showing an increase in CETC in spite of trastuzumab treatment, four have suffered relapse (P = 0.015). Most surprisingly, six of six patients who received trastuzumab only after surgery all had decreasing CETC numbers (Figure 1D) and all are in sustained complete remission after up to 4 years. This difference is highly significant (P < 0.001) in the Kaplan–Meier analysis (Figure 1E). In a Cox regression analysis, lack of response of CETC during anthracycline treatment and increasing CETC to subsequent trastuzumab treatment was highly predictive for relapse (P = 0.0001; hazard ratio = 17.756). Thus, Her2/neu-positive tumors may release a chemotherapy surviving notably aggressive population of tumor cells which trastuzumab may eliminate and/or prevent from settling and growing into metastases or, with stable CETC numbers, may only silence [5.Diermeier S. Horvath G. Knuechel-Clarke R. et al.Epidermal growth factor receptor coexpression modulates susceptibility to herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.Exp Cell Res. 2005; 304: 604-619Crossref PubMed Scopus (140) Google Scholar] capable of regrowing after trastuzumab withdrawal. The question arises if there is an interference between taxane and trastuzumab because patients receiving trastuzumab only after surgery all had left behind Her2/neu-positive trastuzumab responsive cells. But even an excellent reduction of the Her2/neu-positve tumors during neo-adjuvant therapy does not prevent cells with a high metastatic capacity from being released. Therefore, this treatment option should be reconsidered in these patients." @default.
• W2044865080 created "2016-06-24" @default.
• W2044865080 creator A5003405177 @default.
• W2044865080 creator A5005285772 @default.
• W2044865080 creator A5010047260 @default.
• W2044865080 creator A5011116789 @default.
• W2044865080 creator A5027524393 @default.
• W2044865080 creator A5037772379 @default.
• W2044865080 creator A5063234663 @default.
• W2044865080 creator A5067208031 @default.
• W2044865080 creator A5077320747 @default.
• W2044865080 creator A5086109454 @default.
• W2044865080 creator A5088939314 @default.
• W2044865080 date "2008-12-01" @default.
• W2044865080 modified "2023-10-15" @default.
• W2044865080 title "Monitoring circulating epithelial tumor cells (CETCs) during primary systemic chemotherapy including trastuzumab for early prediction of outcome in patients with Her2/neu-positive tumors" @default.
• W2044865080 cites W2034091339 @default.
• W2044865080 cites W2073702030 @default.
• W2044865080 cites W2137935868 @default.
• W2044865080 cites W2138222867 @default.
• W2044865080 cites W2156909204 @default.
• W2044865080 doi "https://doi.org/10.1093/annonc/mdn648" @default.
• W2044865080 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2733124" @default.
• W2044865080 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18820243" @default.
• W2044865080 hasPublicationYear "2008" @default.
• W2044865080 type Work @default.
• W2044865080 sameAs 2044865080 @default.
• W2044865080 citedByCount "6" @default.
• W2044865080 countsByYear W20448650802012 @default.
• W2044865080 countsByYear W20448650802013 @default.
• W2044865080 crossrefType "journal-article" @default.
• W2044865080 hasAuthorship W2044865080A5003405177 @default.
• W2044865080 hasAuthorship W2044865080A5005285772 @default.
• W2044865080 hasAuthorship W2044865080A5010047260 @default.
• W2044865080 hasAuthorship W2044865080A5011116789 @default.
• W2044865080 hasAuthorship W2044865080A5027524393 @default.
• W2044865080 hasAuthorship W2044865080A5037772379 @default.
• W2044865080 hasAuthorship W2044865080A5063234663 @default.
• W2044865080 hasAuthorship W2044865080A5067208031 @default.
• W2044865080 hasAuthorship W2044865080A5077320747 @default.
• W2044865080 hasAuthorship W2044865080A5086109454 @default.
• W2044865080 hasAuthorship W2044865080A5088939314 @default.
• W2044865080 hasBestOaLocation W20448650801 @default.
• W2044865080 hasConcept C121608353 @default.
• W2044865080 hasConcept C126322002 @default.
• W2044865080 hasConcept C143998085 @default.
• W2044865080 hasConcept C2776694085 @default.
• W2044865080 hasConcept C2777863537 @default.
• W2044865080 hasConcept C2777982462 @default.
• W2044865080 hasConcept C2779786085 @default.
• W2044865080 hasConcept C2781190966 @default.
• W2044865080 hasConcept C530470458 @default.
• W2044865080 hasConcept C71924100 @default.
• W2044865080 hasConceptScore W2044865080C121608353 @default.
• W2044865080 hasConceptScore W2044865080C126322002 @default.
• W2044865080 hasConceptScore W2044865080C143998085 @default.
• W2044865080 hasConceptScore W2044865080C2776694085 @default.
• W2044865080 hasConceptScore W2044865080C2777863537 @default.
• W2044865080 hasConceptScore W2044865080C2777982462 @default.
• W2044865080 hasConceptScore W2044865080C2779786085 @default.
• W2044865080 hasConceptScore W2044865080C2781190966 @default.
• W2044865080 hasConceptScore W2044865080C530470458 @default.
• W2044865080 hasConceptScore W2044865080C71924100 @default.
• W2044865080 hasIssue "12" @default.
• W2044865080 hasLocation W20448650801 @default.
• W2044865080 hasLocation W20448650802 @default.
• W2044865080 hasLocation W20448650803 @default.
• W2044865080 hasLocation W20448650804 @default.
• W2044865080 hasOpenAccess W2044865080 @default.
• W2044865080 hasPrimaryLocation W20448650801 @default.
• W2044865080 hasRelatedWork W1875770431 @default.
• W2044865080 hasRelatedWork W1986355551 @default.
• W2044865080 hasRelatedWork W2075255510 @default.
• W2044865080 hasRelatedWork W2153331156 @default.
• W2044865080 hasRelatedWork W2352586227 @default.
• W2044865080 hasRelatedWork W2394860297 @default.
• W2044865080 hasRelatedWork W2804629409 @default.
• W2044865080 hasRelatedWork W2930064598 @default.
• W2044865080 hasRelatedWork W2969515167 @default.
• W2044865080 hasRelatedWork W2990398237 @default.
• W2044865080 hasVolume "19" @default.
• W2044865080 isParatext "false" @default.
• W2044865080 isRetracted "false" @default.
• W2044865080 magId "2044865080" @default.
• W2044865080 workType "article" @default.